Annikka Weissferdt, MD, Dr med, FRCPath

Peer-Reviewed Articles

1. Weissferdt, A, Moran, CA. Solid, cystic, and mucinous spindle cell thymomas (WHO type A). Human Pathology 170, 2026. e-Pub 2026. PMID: 41580205.
2. Weissferdt, A. Diagnostic dilemmas in pulmonary mesenchymal tumors. Seminars in Diagnostic Pathology 43(1), 2026. e-Pub 2026. PMID: 41478263.
3. Ozirmak Lermi, N, Molina Ayala, M, Hernandez, S, Lu, W, Khan, KB, Serrano, A, Lubo Julio, IC, Hamana Zorrilla, L, Tomczak, K, Barnes, S, Dou, J, Liang, Q, Zhang, S, Zhang, Q, Zhang, J, Xu, M, Woodman, SE, Wang, W, Virani, S, Sun, B, Subramanya, S, Song, X, Shaw, KR, Prabhakaran, S, Piubelli, ML, Mohammad, MM, Meric-Bernstam, F, Mendoza, MT, Mallampati, S, Little, L, Lang, W, Knafl, M, Khanduri, I, Gite, S, Arrechedera, C, Raso, G, Tang, X, Sanchez Espiridion, B, Weissferdt, A, Heymach, JV, Zhang, J, Sepesi, B, Cascone, T, Tsao, A, Altan, M, Mehran, RJ, Gibbons, DL, Wistuba, II, Haymaker, CL, Chen, K. Comparison of imaging based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed paraffin-embedded tumor samples. Nature communications 16(1), 2025. e-Pub 2025. PMID: 41006245.
4. Weissferdt, A, Wenig, BM, Moran, CA. Salivary gland-like low-grade clear cell carcinomas of the thoracic cavity. Annals of Diagnostic Pathology 75, 2025. e-Pub 2025. PMID: 39892099.
5. Chou, TY, Dacic, S, Wistuba, II, Beasley, MB, Berezowska, S, Chang, YC, Chung, JH, Connolly, C, Han, Y, Hirsch, F, Hwang, D, Janowczyk, A, Joubert, P, Kerr, K, Lin, DM, Minami, Y, Mino-Kenudson, M, Nicholson, A, Papotti, M, Rekhtman, N, Roden, AC, von der Thüsen, J, Travis, WD, Tsao, MS, Yatabe, Y, Yeh, YC, Bubendorf, L, Chang, WC, Denninghoff, V, Fernandes Tavora, FR, Hayashi, T, Hofman, P, Jain, D, Kim, TJ, Lantuejoul, S, Le Quesne, J, López-Ríos, F, Matsubara, D, Noguchi, M, Radonic, T, Saqi, A, Schalper, K, Shim, HS, Sholl, LM, Weissferdt, A, Cooper, W. Differentiating Separate Primary Lung Adenocarcinomas From Intrapulmonary Metastases With Emphasis on Pathological and Molecular Considerations. Journal of Thoracic Oncology 20(3):311-330, 2025. e-Pub 2025. PMID: 39579981.
6. Lermi NO, Ayala MM, Ruiz SH, Lu W, Khan K, Serrano A, Lubo I, Hamana L, Tomczak K, Barnes S, Dou J, Liang Q, Team RTI, Raso MG, Tang X, Jiang M, Sanchez-Espiridion B, Weissferdt A, Heymach J, Zhang J, Sepesi B, Cascone T, Tsao A, Altan M, Mehran R, Gibbons D, Wistuba I, Haymaker C, Chen K, Solis Soto LM. Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samples. Nat Commun, 2025. PMID: 39877088.
7. Weissferdt, A, Moran, CA. Thoracic solitary fibrous tumors with small cell features. Annals of Diagnostic Pathology 73, 2024. e-Pub 2024. PMID: 38878688.
8. Weissferdt, A, Moran, CA. Clear cell stromal tumor of the lung. Pathology, research and practice 264:155722, 2024. e-Pub 2024. PMID: 39556929.
9. Zhou, N, Leung, CH, William Jr, WN, Weissferdt, A, Pataer, A, Godoy, M, Carter, B, Fossella, FV, Tsao, A, Blumenschein, GR, Le, X, Zhang, J, Skoulidis, F, Kurie, JM, Altan, M, Lu, C, Glisson, BS, Byers, LA, Elamin, YY, Mehran, RJ, Rice, DC, Walsh, GL, Hofstetter, WL, Roth, JA, Tran, HT, Wu, J, Solis Soto, LM, Kadara, HN, Swisher, SG, Vaporciyan, AA, Gibbons, DL, Lin, HY, Jack Lee, J, Heymach, JV, Vailati Negrao, M, Sepesi, B, Cascone, T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. Journal for immunotherapy of cancer 12(10), 2024. e-Pub 2024. PMID: 39448200.
10. Weissferdt A, Moran CA. Primary extraskeletal osteosarcomas of the pleura: A clinicopathological, immunohistochemical, and molecular analysis of 4 cases. Hum Pathol 152:105635, 2024. e-Pub 2024. PMID: 39117026.
11. Weissferdt A, Moran CA. Atypical Thymoma (WHO Type B3) with Prominent Microcystic and Mucoid Changes Mimicking Thymic Mucoepidermoid Carcinoma: A Clinicopathological and Immunohistochemical Study of Five Cases. International Journal of Surgical Pathology 33(2):394-398, 2024. e-Pub 2024. PMID: 39150796.
12. Weissferdt, A, Moran, CA. Primary thymic adenoid cystic carcinoma with high-grade transformation: A clinicopathological and immunohistochemical analysis of 4 cases. Pathology Research and Practice 259, 2024. e-Pub 2024. PMID: 38810375.
13. Seth, S, Chen, R, Liu, Y, Fujimoto, J, Hong, L, Reuben, A, Varghese, S, Behrens, MC, McDowell, TL, Solis Soto, LM, Haymaker, CL, Weissferdt, A, Kalhor, N, Wu, J, Le, X, Vokes, N, Cheng, C, Heymach, JV, Gibbons, DL, Futreal, A, Wistuba, II, Kadara, HN, Zhang, J, Moran, C, Zhang, J. Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes. Cancer Innovation 3(3), 2024. e-Pub 2024. PMID: 38947760.
14. Feldman, HA, Sepesi, B, Leung, CH, Lin, Y, Weissferdt, A, Pataer, A, William Jr, WN, Walsh, GL, Rice, DC, Roth, JA, Mehran, RJ, Hofstetter, WL, Antonoff, MB, Rajaram, R, Gibbons, DL, Lee, JJ, Heymach, JV, Vaporciyan, AA, Swisher, SG, Cascone, T. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery 167(4):1444-1453.e4, 2024. e-Pub 2024. PMID: 37816395.
15. Deutsch, JS, Cottrell, T, Chen, KY, de Andrea, CE, Baraban, EG, Fiset, PO, Jedrych, J, Orr, C, Salgado, R, Schürch, CM, Scolyer, RA, Seethala, RR, Sholl, LM, Signoretti, S, Tetzlaff, M, Weissferdt, A, Xu, X, Ziai, J, Cimino-Mathews, A, Taube, JM. Pan-tumor harmonization of pathologic response assessment for standardized data collection in neoadjuvant IO trials (PATHdata). Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
16. Weissferdt, A, Leung, CH, Lin, Y, Sepesi, B, William Jr, WN, Swisher, SG, Cascone, T, Lee, JJ, Pataer, A. Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Modern Pathology 37(1), 2024. e-Pub 2024. PMID: 37844869.
17. Weissferdt A. Non-Neoplastic Thoracic Cysts: A Clinicopathologic Study of 136 Cases. Am J Surg Pathol 47(12):1349-1363, 2023. e-Pub 2023. PMID: 37642507.
18. Dacic, S, Travis, WD, Redman, MW, Saqi, A, Cooper, W, Borczuk, AC, Chung, JH, Glass, C, Lopez, JM, Roden, AC, Sholl, LM, Weissferdt, A, Posadas, J, Walker, A, Zhu, H, Wijeratne, MT, Connolly, C, Wynes, MW, Bota-Rabassedas, N, Sanchez Espiridion, B, Lee, JJ, Berezowska, S, Chou, TY, Kerr, K, Nicholson, A, Poleri, C, Schalper, K, Tsao, MS, Carbone, DP, Ready, NE, Cascone, T, Heymach, JV, Sepesi, B, Shu, CA, Rizvi, NA, Sonett, J, Altorki, N, Provencio, M, Bunn, P, Kris, MG, Belani, C, Kelly, K, Wistuba, II. International Association for the Study of Lung Cancer (IASLC ) Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. Journal of Thoracic Oncology 18(10):1290-1302, 2023. e-Pub 2023. PMID: 37702631.
19. Weissferdt A, Moran C.. PAX5 and CD70 are expressed in thymic carcinoma but not in atypical thymoma (WHO type B3 thymoma): an immunohistochemical analysis of 60 cases. Journal of Clinical Pathology 77(11):761-765, 2023. e-Pub 2023. PMID: 37696593.
20. Weissferdt A, Moran CA. Basaloid Squamous Cell Carcinomas of the Thymus With Prominent B-Cell Lymphoid Hyperplasia: A Clinicopathologic and Immunohistochemical Study of 10 Cases. Am J Surg Pathol 47(9):1039-1044, 2023. e-Pub 2023. PMID: 37341090.
21. Zhou, N, Bell, CS, Feldman, HA, Haymaker, CL, Hofstetter, WL, Tsao, A, Mehran, RJ, Rice, DC, Sepesi, B, Tomczak, K, Weissferdt, A, Parra Cuentas, ER, Zhang, J, Lee, PP, Rajaram, R, Vaporciyan, AA. Tumor thickness in mesothelioma predicts differential response to neoadjuvant therapy and survival. Journal of Thoracic and Cardiovascular Surgery 166(2):362-371.e9, 2023. e-Pub 2023. PMID: 36737380.
22. Deboever N, Zhou N, McGrail DJ, Tomczak K, Oliva JL, Feldman HA, Parra E, Zhang J, Lee PP, Antonoff MB, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Swisher SS, Vaporciyan AA, Altan M, Weissferdt A, Tsao AS, Haymaker CL, Sepesi B. Radiographic response to neoadjuvant therapy in pleural mesothelioma should serve as a guide for patient selection for cytoreductive operations. Front Oncol 13:1216999, 2023. e-Pub 2023. PMID: 37637041.
23. Weissferdt A, Moran CA. Primary epithelioid hemangioendotheliomas and angiosarcomas of the pleura: a clinicopathological and immunohistochemical analysis of 13 cases. Hum Pathol 138:68-75, 2023. e-Pub 2023. PMID: 37364825.
24. Weissferdt A, Moran CA. Chromophobe-like carcinoma of the thymus: A clinicopathological and immunohistochemical correlation of 5 cases. Pathol Res Pract 248:154629, 2023. e-Pub 2023. PMID: 37348289.
25. Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
26. Katz MS, Weissferdt A, Antonoff MB. Histologic subtypes of non-small cell lung cancer: can we further personalize radiation therapy?. Int J Radiat Oncol Biol Phys 115(4):906-908, 2023. e-Pub 2023. PMID: 36822787.
27. Weissferdt A, Sepesi B, Ning J, Hermsen M, Ferrarotto R, Glisson B, Hanna E, Bell D. Optimal Combination of Neuroendocrine Markers for the Detection of High-Grade Neuroendocrine Tumors of the Sinonasal Tract and Lung. Curr Oncol Rep 25(1):1-10, 2023. e-Pub 2023. PMID: 36422794.
28. Francisco-Cruz A, Rocha P, Reuben A, Krishnan SN, Das P, Chen R, Quek K, Li J, Parra ER, Solis Soto LM, Barua S, Jiang M, Lazcano R, Chow CW, Behrens C, Gumbs C, Little LD, Fukuoka J, Kalhor N, Weissferdt A, Kadara H, Heymach JV, Swisher S, Sepesi B, Rao A, Moran CA, Zhang J, Lee JJ, Fujimoto J, Futreal A, Wistuba II, Peterson C, Zhang J. Analysis of immune intratumor heterogeneity highlights immunoregulatory and coinhibitory lymphocytes as hallmarks of recurrence in stage I NSCLC. Mod Pathol 36(1), 2023. e-Pub 2023. PMID: 36788067.
29. Barletta JA, Gilday SD, Afkhami M, Bell D, Bocklage T, Boisselier P, Chau NG, Cipriani NA, Costes-Martineau V, Ghossein RA, Hertzler HJ, Kramer AM, Limaye S, Lopez CA, Ng T, Weissferdt A, Xu B, Zhang S, French CA. NUTM1-rearranged carcinoma of the thyroid: a distinct subset of NUT carcinoma characterized by frequent NSD3-NUTM1 fusions. Am J Surg Pathol 46(12):1706-1715, 2022. e-Pub 2022. PMID: 36040068.
30. Sepesi B, Zhou N, William WN, Lin HY, Leung CH, Weissferdt A, Mitchell KG, Pataer A, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Negrao MV, Tsao AS, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 164(5):1327-1337, 2022. e-Pub 2022. PMID: 35190177.
31. Pataer A, Weissferdt A, Correa AM, Vaporciyan AA, Sepesi B, Heymach JV, Berezowska S, Cascone T, Swisher SG. Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. JTO Clin Res Rep 3(11):100420, 2022. e-Pub 2022. PMID: 36389133.
32. Akhave N, Zhang J, Bayley E, Frank M, Chiou SH, Behrens C, Chen R, Hu X, Parra ER, Lee WC, Swisher S, Solis L, Weissferdt A, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Heymach JV, Lee JJ, Wistuba II, Andrew Futreal P, Zhang J, Fujimoto J, Reuben A. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. Lung Cancer 172:19-28, 2022. e-Pub 2022. PMID: 35973335.
33. Fang H, Toruner GA, Tang Z, Tang G, Weissferdt A, Tashakori M, El Hussein S, Thakral B, Quesada AE, Wang W, Patel KP, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE, Jelloul FZ. Primary mediastinal germ cell tumor and clonally related and unique hematologic neoplasms with i(12p) and TP53 mutation: A report of two cases. Ann Diagn Pathol 59:151951, 2022. e-Pub 2022. PMID: 35489185.
34. Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MA, McGrail DJ, Weissferdt A, Lin SY, Lee Y, Suzuki E, Kovacs JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Heffernan TP, Negrao MV, Gibbons DL, Team I. A shared nearest neighbors approach and interactive browser for network analysis of a comprehensive non-small cell lung cancer dataset. JCO Clin Cancer Inform 6:e2200040, 2022. e-Pub 2022. PMID: 35944232.
35. Maroongroge S, Weissferdt A, Buszek S, Rice DC, Smith BD, Gandhi SJ. Management of Bronchial Adenoma/Ciliated Muconodular Papillary Tumor with Definitive Stereotactic Body Radiation Therapy (SBRT): A Case Report. Clin Lung Cancer 23(5):e335-e338, 2022. e-Pub 2022. PMID: 35613996.
36. Shah P, Forget MA, Frank ML, Federico L, Jiang P, Khairullah R, Wistuba II, Chow CW, Long Y, Fujimoto J, Lin SY, Maitra A, Negrao MV, Mitchell KG, Weissferdt A, Vaporciyan AA, Cascone T, Roth J, Zhang J, Sepesi B, Gibbons DL, Heymach JV, Haymaker C, McGrail DJ, Reuben A, Bernatchez C. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer 10(2):e003082, 2022. e-Pub 2022. PMID: 35110355.
37. Federico L, McGrail DJ, Bentebibel SE, Haymaker C, Ravelli A, Forget MA, Karpinets T, Jiang P, Reuben A, Negrao MV, Li J, Khairullah R, Zhang J, Weissferdt A, Vaporciyan AA, Antonoff MB, Walsh G, Lin SY, Futreal A, Wistuba I, Roth J, Byers LA, Gaudreau PO, Uraoka N, Cruz AF, Dejima H, Lazcano RN, Solis LM, Parra ER, Lee JJ, Swisher S, Cascone T, Heymach JV, Zhang J, Sepesi B, Gibbons DL, Bernatchez C. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small cell lung cancer. Ann Oncol 33(1):42-56, 2022. e-Pub 2022. PMID: 34653632.
38. Tang M, Abbas HA, Negrao MV, Ramineni M, Hu X, Hubert SM, Fujimoto J, Reuben A, Varghese S, Zhang J, Li J, Chow CW, Mao X, Song X, Lee WC, Wu J, Little L, Gumbs C, Behrens C, Moran C, Weissferdt A, Lee JJ, Sepesi B, Swisher S, Cheng C, Kurie J, Gibbons D, Heymach JV, Wistuba II, Futreal PA, Kalhor N, Zhang J. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun 12(7081):7081, 2021. e-Pub 2021. PMID: 34873156.
39. Pataer A, Weissferdt A, Vaporciyan AA, Correa AM, Sepesi B, Wistuba II, Heymach JV, Cascone T, Swisher SG. Evaluation of Pathologic Response in Lymph Nodes of Lung Cancer Patients Receiving Neoadjuvant Chemotherapy. J Thorac Oncol 16(8):1289-1297, 2021. e-Pub 2021. PMID: 33857666.
40. Cascone T, Weissferdt A, Godoy M, Jr WW, Leung CH, Lin H, Basu S, Yadav S, Pataer A, Mitchell K, Wadud Khan MA, Shi Y, Haymaker C, Solis L, Parra ER, Kadara H, Wistuba II, Sharma P, Allison J, Ajami N, Wargo J, Jenq R, Gibbons D, Lee JJ, Swisher SG, Vaporciyan A, Heymach JV, Sepesi B. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun 12(1):5045, 2021. e-Pub 2021. PMID: 34413300.
41. Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. CD73 expression defines immune, molecular and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother 70(7):1965-1976, 2021. e-Pub 2021. PMID: 33416944.
42. Subbiah V, Shen T, Tetzlaff M, Weissferdt A, Byers LA, Cascone T, Behrang A, Meric-Bernstam F, Mooers BHM, Rothenberg SM, Ebata K, Wu J. Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. Ann Oncol 32(6):817-819, 2021. e-Pub 2021. PMID: 33617938.
43. Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
44. Gaudreau PO, Negrao MV, Mitchell KG, Reuben A, Corsini EM, Li J, Karpinets TV, Wang Q, Diao L, Wang J, Federico L, Parra-Cuentas ER, Khairullah R, Behrens C, Correa AM, Gomez D, Little L, Gumbs C, Kadara HN, Fujimoto J, McGrail DJ, Vaporciyan AA, Swisher SG, Walsh G, Antonoff MB, Weissferdt A, Tran H, Roarty E, Haymaker C, Bernatchez C, Zhang J, Futreal PA, Wistuba II, Cascone T, Heymach JV, Sepesi B, Zhang J, Gibbons DL. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. J Thorac Oncol 16(1):127-139, 2021. e-Pub 2021. PMID: 33096269.
45. Corsini EM, Weissferdt A, Pataer A, Zhou N, Antonoff MB, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Cascone T, Heymach JV, Swisher SG, Sepesi B. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. Eur J Cardiothorac Surg 59(1):100-108, 2021. e-Pub 2021. PMID: 32864702.
46. Wolf JL, van Nederveen F, Blaauwgeers H, Marx A, Nicholson AG, Roden AC, Ströbel P, Timens W, Weissferdt A, von der Thüsen J, den Bakker MA. Interobserver variation in the classification of thymic lesions including biopsies and resection specimens in an international digital microscopy panel. Histopathology 77(5):734-741, 2020. e-Pub 2020. PMID: 32506527.
47. Mitchell KG, Amini B, Wang Y, Carter BW, Godoy MCB, Parra ER, Behrens C, Villalobos P, Reuben A, Lee JJ, Weissferdt A, Moran CA, Fujimoto J, Sepesi B, Walsh GL, Vaporciyan AA, Hofstetter WL, William WN, Gibbons DL, Wang J, Hwu P, Swisher SG, Piwnica-Worms D, Kadara H, Wistuba II, Heymach JV, Peng W, Cascone T. 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother 69(8):1519-1534, 2020. e-Pub 2020. PMID: 32300858.
48. Weissferdt A, Pataer A, Vaporciyan A, Correa AM, Sepesi B, Moran CA, Wistuba II, Roth JA, Shewale JB, Heymach JV, Kalhor N, Cascone T, Hofstetter WL, Lee JJ, Swisher SG. Agreement on major pathological response in NSCLC patients receiving neoadjuvant chemotherapy. Clin Lung Cancer 21(4):341-348, 2020. e-Pub 2020. PMID: 32279936.
49. Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JV. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res 26(14):3525-3536, 2020. e-Pub 2020. PMID: 32193228.
50. Safa H, Bhosale P, Weissferdt A, Oliva ICG. Difficulties in differentiating between checkpoint inhibitor pneumonitis and lung metastasis in a patient with melanoma. Immunotherapy 12(5):293-298, 2020. e-Pub 2020. PMID: 32295435.
51. Nelson DB, Mitchell KG, Wang J, Fujimoto J, Godoy M, Behrens C, Zheng X, Zhang J, Sepesi B, Vaporciyan AA, Hofstetter WL, Mehran RJ, Rice DC, Walsh GL, Swisher SG, Moran CA, Kalhor N, Weissferdt A, Wistuba II, Roth JA, Antonoff MB. Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities. J Thorac Dis 12(3):329-337, 2020. e-Pub 2020. PMID: 32274099.
52. Mitchell KG, Negrao MV, Parra ER, Li J, Zhang J, Dejima H, Vaporciyan AA, Swisher SG, Weissferdt A, Antonoff MB, Cascone T, Roarty E, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Sepesi B. Lymphovascular invasion is associated with mutational burden and PD-L1 in resected lung cancer. Ann Thorac Surg 109(2):358-366, 2020. e-Pub 2020. PMID: 31550464.
53. Wang S, Wang T, Yang L, Yang DM, Fujimoto J, Yi F, Luo X, Yang Y, Yao B, Lin S, Moran C, Kalhor N, Weissferdt A, Minna J, Xie Y, Wistuba II, Mao Y, Xiao G. ConvPath: A software tool for lung adenocarcinoma digital pathological image analysis aided by a convolutional neural network. EBioMedicine 50:103-110, 2019. e-Pub 2019. PMID: 31767541.
54. Luo X, Yin S, Yang L, Fujimoto J, Yang Y, Moran C, Kalhor N, Weissferdt A, Xie Y, Gazdar A, Minna J, Wistuba II, Mao Y, Xiao G. Development and validation of a pathology image analysis-based predictive model for lung adenocarcinoma prognosis - a multi-cohort study. Sci Rep 9(1):6886, 2019. e-Pub 2019. PMID: 31053738.
55. Weissferdt A, Kalhor N, Rodriguez Canales J, Fujimoto J, Wistuba II, Moran CA. Primary mediastinal yolk sac tumors: An immunohistochemical analysis of 14 cases. Appl Immunohistochem Mol Morphol 27(2):125-133, 2019. e-Pub 2019. PMID: 27643524.
56. . Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 158:911-919, 2019. e-Pub 2019.
57. Mitchell KG, Parra ER, Nelson DB, Corsini EM, Zhang J, Vaporciyan AA, Hofstetter WL, Mehran R, Swisher SG, Rice D, Sepesi S, Walsh GL, Behrens C, Kalhor N, Weissferdt A, Moran CA, Skoulidis F, Wistuba II, Fujimoto J, Roth JA, Antonoff MB. Intratumoral LKB1/STK11 Expression Correlates with Immune Cell Infiltration and Oncologic Outcomes Following Resection of Lung Adenocarcinoma. Ann Thorac Surg, 2019. e-Pub 2019.
58. Shaw A, Morrell M, Weissferdt A, Hayes-Jordan A, Harrison D. Malignant Transformation of Testicular Teratoma to PNET, Adenocarcinoma, and Osteosarcoma with Complete Remission after Surgery and Combination Chemotherapy in a Young Adult Male. Case Rep Oncol Med:8460603, 2018. e-Pub 2018. PMID: 30402315.
59. Weissferdt A. Pulmonary Carcinomas With Mucinous and Neuroendocrine Differentiation: Expanding the Spectrum of Amphicrine Carcinomas. Am J Surg Pathol 9(42), 2018. e-Pub 2018. PMID: 30001241.
60. Shewale JB, Mitchell KG, Nelson DB, Conley AP, Rice DC, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Mehran RJ, Vaporciyan AA, Weissferdt A, Sepesi B. Predictors of survival after resection of primary sarcomas of the chest wall: A large, single-institution series. J Surg Oncol 3(118), 2018. e-Pub 2018. PMID: 30109699.
61. Lee WC, Diao L, Wang J, Zhang J, Roarty EB, Varghese S, Chow CW, Fujimoto J, Behrens C, Cascone T, Peng W, Kalhor N, Moran CA, Weissferdt A, Johnson FM, Jr WW, Swisher SG, Lee JJ, Hong WK, Heymach JV, Wistuba II, Futreal PA, Zhang J. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Mod Pathol 6(31), 2018. e-Pub 2018. PMID: 29410488.
62. Parra ER, Villalobos P, Zhang J, Behrens C, Mino B, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Heymach JV, Moran C, Zhang J, Lee J, Rodriguez-Canales J, Gibbons D, Wistuba II. Immunohistochemical and Image Analysis-based Study Demonstrate that Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. J Thorac Oncol 6(13), 2018. e-Pub 2018. PMID: 29526824.
63. Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, William WN, Zhang J, Lee J, Cascone T, Heymach JV, Forget MA, Haymaker C, Bernatchez C, Kalhor N, Weissferdt A, Moran C, Zhang J, Vaporciyan A, Gibbons DL, Sepesi B, Wistuba II. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer 1(6):48, 2018. e-Pub 2018. PMID: 29871672.
64. Weissferdt A, Kalhor N, Bishop JA, Jang SJ, Ro JY, Petersson F, Wu BC, Langman G, Bancroft H, Bi Y, Meng Y, Medeiros F, Brunnström H, Spagnolo D, Chai SM, Laycock A, Wakely PE, Elmberger G, Soares FA, Campos AH, Gümürdülü D, Alvarado-Cabrero I, Coppola D, Correa AM, Rice D, Mehran RJ, Sepesi B, Walsh G, Kaiser L, Moran CA. Thymoma: A clinicopathological correlation of 1470 cases from the Thymic International Group. Hum Pathol 73:7-15, 2018. e-Pub 2018. PMID: 28851660.
65. Cascone T, Gold KA, Swisher S, Liu D, Fossella FV, Sepesi B, Pataer A, Weissferdt A, Kalhor N, Vaporcyian A, Hofstetter W, Wistuba I, Heymach JV, Kim ES, William WN. Induction cisplatin docetaxel followed by surgery and erlotinib in non-small cell lung cancer. Ann Thorac Surg 105(2):418-424, 2018. e-Pub 2018. PMID: 29217088.
66. Cherian SV, Estrada-y-Martin RM, Billah S, Weissferdt A. A 53-year old man with a bronchial mass and multiple bone lesions. Chest 152(5):e115-e119, 2017. e-Pub 2017. PMID: 29126536.
67. Sepesi B, Cuentas EP, Canales JR, Behrens C, Correa AM, Vaporciyan A, Weissferdt A, Kalhor N, Moran C, Swisher S, Wistuba I. Programmed death cell ligand 1 (PD-L1) is associated with survival in stage I non-small cell lung cancer. Semin Thorac Cardiovasc Surg 29(3):408-415, 2017. e-Pub 2017. PMID: 29195578.
68. Weissferdt A, Kalhor N, Moran CA. Cutaneous basal cell carcinoma with distant metastasis to thorax and bone : A clinicopathological and immunohistochemical study of 15 cases. Virchows Arch 470(6):687-694, 2017. e-Pub 2017. PMID: 28391557.
69. Weissferdt A, Fujimoto J, Kalhor N, Rodriguez J, Bassett R, Wistuba II, Moran CA. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol 30(6):826-33, 2017. e-Pub 2017. PMID: 28281549.
70. Cherian SV, Estrada-Y-Martin RM, Irani AD, Zhou J, Weissferdt A. A 33-Year-Old Woman With a Fluorodeoxyglucose-Avid Left Lower Lobe Mass. Chest 151(5):e119-e122, 2017. e-Pub 2017. PMID: 28483135.
71. Weissferdt A, Kalhor N, Correa AM, Moran CA. "Sarcomatoid" carcinomas of the lung: a clinicopathologic study of 86 cases with a new perspective on tumor classification. Hum Pathol 63(5):14-26, 2017. e-Pub 2017. PMID: 27993578.
72. Weissferdt A, Kalhor N, Rodriguez Canales J, Fujimoto J, Wistuba II, Moran CA. Spindle cell and pleomorphic ("sarcomatoid") carcinomas of the lung: an immunohistochemical analysis of 86 cases. Hum Pathol 59(1):1-9, 2017. e-Pub 2017. PMID: 27569293.
73. Weissferdt A, Kalhor N, Moran CA. Pleuromediastinal epithelial-myoepithelial carcinomas: a clinicopathologic and immunohistochemical study of two cases. Am J Clin Pathol 146(6):736-740, 2016. e-Pub 2016. PMID: 27864182.
74. Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Zhang J, Gibbons DL, Heymach JV, Sepesi B, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Kadara H, Moran C, Lee JJ, Wistuba II. Image Analysis-Based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-Small Cell Lung Carcinoma Patients. Clin Cancer Res 22(24):6278-6289, 2016. e-Pub 2016. PMID: 27252415.
75. Weissferdt A, Kalhor N, Petersson F, Moran CA. Ectopic Hamartomatous Thymoma-New Insights Into a Challenging Entity: A Clinicopathologic and Immunohistochemical Study of 9 Cases. Am J Surg Pathol 40(11):1571-76, 2016. e-Pub 2016. PMID: 27428736.
76. Weissferdt A, Kalhor N, Moran CA. Intrathoracic glomus tumors and glomangiosarcomas: a clinicopathological and immunohistochemical study of 14 cases with emphasis on anatomic distribution. Virchows Arch 469(5):541-46, 2016. e-Pub 2016. PMID: 27591766.
77. Weissferdt A, Kalhor N, Moran CA. Sebaceous Lymphadenoma of The Thymus: A clinicopathological and immunohistochemical study of two cases. Hum Pathol 56(10):189-93, 2016. e-Pub 2016. PMID: 27374279.
78. Weissferdt A, Kalhor N, Moran CA. Thymomas With Extensive Clear Cell Component: A Clinicopathologic and Immunohistochemical Study of Nine Cases. Am J Clin Pathol 146(1):132-6, 2016. e-Pub 2016. PMID: 27371363.
79. Weissferdt A, Moran CA. Primary giant cell carcinomas of the lung: a clinicopathological and immunohistochemical analysis of seven cases. Histopathology 68(5):680-5, 2016. e-Pub 2016. PMID: 26259572.
80. Weissferdt A, Moran CA. Neuroendocrine Differentiation in Thymic Carcinomas: A Diagnostic Pitfall: An Immunohistochemical Analysis of 27 Cases. Am J Clin Pathol 145(3):393-400, 2016. e-Pub 2016. PMID: 27124922.
81. Weissferdt A, Moran CA. Ectopic primary intrathyroidal thymoma: a clinicopathological and immunohistochemical analysis of 3 cases. Hum Pathol 49(3):71-6, 2016. e-Pub 2016. PMID: 26826412.
82. Weissferdt A, Kalhor N, Moran CA. Cystic well-differentiated squamous cell carcinoma of the thymus: a clinicopathological and immunohistochemical study of six cases. Histopathology 68(3):333-8, 2016. e-Pub 2016. PMID: 26031186.
83. Falk N, Weissferdt A, Kalhor N, Moran CA. Primary Pulmonary Salivary Gland-type Tumors: A Review and Update. Adv Anat Pathol 23(1):13-23, 2016. e-Pub 2016. PMID: 26645458.
84. . Image analysis-based assessment of programmed cell death ligand 1 and tumor-associated immune cells density defines distinct intratumoral microenvironment groups in non-small cell lung carcinoma patients. Clin Cancer Res 22:6278-6289, 2016. e-Pub 2016.
85. Bell D, Hanna EY, Agaimy A, Weissferdt A. Reappraisal of sinonasal undifferentiated carcinoma: SMARCB1 (INI1)-deficient sinonasal carcinoma: a single-institution experience. Virchows Arch 467(6):649-656, 2015. e-Pub 2015. PMID: 26407663.
86. Weissferdt A, Tang X, Suster S, Wistuba II, Moran CA. Pleuropulmonary Meningothelial Proliferations: Evidence for a Common Histogenesis. Am J Surg Pathol 39(12):1673-8, 2015. e-Pub 2015. PMID: 26291511.
87. Weissferdt A, Kalhor N, Moran C. Primary thymic cholesteroloma: A clinicopathological correlation of four cases of an unusual benign lesion. Virchows Arch 467(5):609-11, 2015. e-Pub 2015. PMID: 26266777.
88. Zenali MJ, Weissferdt A, Solis LM, Ali S, Tang X, Mehran RJ, Wistuba II, Moran CA, Kalhor N. An update on clinicopathological, immunohistochemical, and molecular profiles of colloid carcinoma of the lung. Human Pathol 46(6):836-42, 2015. e-Pub 2015. PMID: 25776025.
89. Weissferdt A, Kalhor N, Moran CA. Ewing sarcoma with extensive neural differentiation: a clinicopathologic, immunohistochemical, and molecular analysis of three cases. Am J Clin Pathol 143(5):659-64, 2015. e-Pub 2015. PMID: 25873499.
90. Falk N, Habra M, Weissferdt A, Roy Chowdhuri S. ACTH-producing thymic neuroendocrine carcinoma with oncocytic features: a case report and review of the literature. Diagn Cytopathol 43(4):329-34, 2015. e-Pub 2015. PMID: 25354884.
91. Weissferdt A, Rodriguez J, Liu H, Fujimoto J, Wistuba II, Moran CA. Primary mediastinal seminomas: a comprehensive immunohistochemical study with a focus on novel markers. Human Pathol 46(3):376-83, 2015. e-Pub 2015. PMID: 25576290.
92. Weissferdt A, Moran CA. Mediastinal seminoma with florid follicular lymphoid hyperplasia: a clinicopathological and immunohistochemical study of six cases. Virchows Arch 466(2):209-15, 2015. e-Pub 2015. PMID: 25425477.
93. Weissferdt A, Kalhor N, Liu H, Rodriguez J, Fujimoto J, Tang X, Wistuba II, Moran CA. Thymic neuroendocrine tumors (paraganglioma and carcinoid tumors): a comparative immunohistochemical study of 46 cases. Hum Pathol 45(12):2463-70, 2014. e-Pub 2014. PMID: 25294372.
94. Weissferdt A, Kalhor N, Moran CA. Combined thymoma-thymic seminoma. Report of 2 cases of a heretofore unreported association. Human Pathology 45(10):2168-72, 2014. e-Pub 2014. PMID: 25090916.
95. Weissferdt A, Moran CA. Spindle cell thymomas with neuroendocrine morphology: a clinicopathological and immunohistochemical study of 18 cases. Histopathology 65(1):111-8, 2014. e-Pub 2014. PMID: 24702597.
96. Weissferdt A, Moran CA. Lipomatous tumors of the anterior mediastinum with muscle differentiation: a clinicopathological and immunohistochemical study of three cases. Virchows Arch 464(4):489-93, 2014. e-Pub 2014. PMID: 24558031.
97. Weissferdt A, Phan A, Suster S, Moran CA. Adrenocortical Carcinoma: A Comprehensive Immunohistochemical Study of 40 Cases. Appl Immunohistochem Mol Morphol 22(1):24-30, 2014. e-Pub 2014. PMID: 23531850.
98. Weissferdt A, Tang X, Wistuba II, Moran CA. Comparative immunohistochemical analysis of pulmonary and thymic neuroendocrine carcinomas using PAX8 and TTF-1. Mod Pathol 26(12):1554-60, 2013. e-Pub 2013. PMID: 23787439.
99. Mahmood L, Demian N, Weinstock YE, Weissferdt A. Mandibular Nerve Schwannoma Resection Using Sagittal Split Ramus Osteotomy. J Oral Maxillofac Surg 71(11):1861-72, 2013. e-Pub 2013. PMID: 23891013.
100. Weissferdt A, Kalhor N, Marom EM, Benveniste MF, Godoy MC, Correa AM, Swisher SG, Moran CA. Early-stage pulmonary adenocarcinoma (T1N0M0): a clinical, radiological, surgical, and pathological correlation of 104 cases. The MD Anderson Cancer Center Experience. Mod Pathol 26(8):1065-75, 2013. e-Pub 2013. PMID: 23542459.
101. Weissferdt A, Moran CA. The impact of neoadjuvant chemotherapy on the histopathological assessment of thymomas: a clinicopathological correlation of 28 cases treated with a similar regimen. Lung 191(4):379-83, 2013. e-Pub 2013. PMID: 23652348.
102. Weissferdt A, Moran CA. Thymomas with prominent glandular differentiation: a clinicopathologic and immunohistochemical study of 12 cases. Hum Pathol 44(8):1612-6, 2013. e-Pub 2013. PMID: 23528863.
103. Weissferdt A, Phan A, Suster S, Moran CA. Myxoid adrenocortical carcinoma: A clinicopathologic and immunohistochemical study of 7 cases, including 1 case with lipomatous metaplasia. Am J Clin Pathol 139(6):780-6, 2013. e-Pub 2013. PMID: 23690121.
104. Weissferdt A, Phan A, Suster S, Moran CA. Primary rhabdoid adrenocortical carcinoma: A clinicopathological and immunohistochemical study of 3 cases. Histopathology 62(5):771-7, 2013. e-Pub 2013. PMID: 23445527.
105. Weissferdt A, Moran CA. Desmoplastic spindle cell thymomas: A clinicopathologic and immunohistochemical study of 14 cases. Hum Pathol 44(4):623-7, 2013. e-Pub 2013. PMID: 23084585.
106. Weissferdt A, Moran CA. Thymic hyperplasia with lymphoepithelial sialadenitis (LESA)-like features: A clinicopathologic and immunohistochemical study of 4 cases. Am J Clin Pathol 138(6):816-22, 2012. e-Pub 2012. PMID: 23161715.
107. Weissferdt A, Moran CA. Primary pulmonary primitive neuroectodermal tumor (PNET): A clinicopathological and immunohistochemical study of 6 cases. Lung 190(6):677-83, 2012. e-Pub 2012. PMID: 22802134.
108. Weissferdt A, Moran CA. Thymomas with prominent signet ring cell-like features: A clinicopathologic and immunohistochemical study of 10 cases. Hum Pathol 43(11):1881-6, 2012. e-Pub 2012. PMID: 22575262.
109. Weissferdt A, Lin H, Woods D, Tang X, Fujimoto J, Wistuba II, Moran CA. HER family receptor and ligand status in thymic carcinoma. Lung Cancer 77(3):515-21, 2012. e-Pub 2012. PMID: 22726920.
110. Weissferdt A, Moran CA. Micronodular thymic carcinoma with lymphoid hyperplasia: A clinicopathological and immunohistochemical study of 5 cases. Mod Pathol 25(7):993-9, 2012. e-Pub 2012. PMID: 22388764.
111. Weissferdt A, Moran CA. Thymic carcinoma, part 1: A clinicopathologic and immunohistochemical study of 65 cases. Am J Clin Pathol 138(1):103-14, 2012. e-Pub 2012. PMID: 22706865.
112. Weissferdt A, Moran CA. Thymic carcinoma, part 2: A clinicopathologic correlation of 33 cases with a proposed staging system. Am J Clin Pathol 138(1):115-21, 2012. e-Pub 2012. PMID: 22706866.
113. Weissferdt A, Moran CA. Anaplastic thymic carcinoma: A clinicopathologic and immunohistochemical study of 6 cases. Hum Pathol 43(6):874-7, 2012. e-Pub 2012. PMID: 22055398.
114. Moran CA, Weissferdt A, Kalhor N, Solis LM, Behrens C, Wistuba II, Suster S. Thymomas I: A clinicopathologic correlation of 250 cases with emphasis on the World Health Organization schema. Am J Clin Pathol 137(3):444-50, 2012. e-Pub 2012. PMID: 22338057.
115. Weissferdt A, Moran CA. Primary MALT-type lymphoma of the thymus: A clinicopathological and immunohistochemical study of 6 cases. Lung 189(6):461-6, 2011. e-Pub 2011. PMID: 21989494.
116. Weissferdt A, Moran CA. Pulmonary salivary gland-type tumors with features of malignant mixed tumor (carcinoma ex pleomorphic adenoma): A clinicopathologic study of 5 cases. Am J Clin Pathol 136(5):793-8, 2011. e-Pub 2011. PMID: 22031319.
117. Weissferdt A, Moran CA. Microcystic squamous cell carcinoma of the lung: A clinicopathologic study of 3 cases. Am J Clin Pathol 136(3):436-41, 2011. e-Pub 2011. PMID: 21846920.
118. Watkins J, Slade JH, Phan A, Eng C, Weissferdt A, Overman MJ. Fatal pulmonary toxicity associated with oxaliplatin administration. Clin Colorectal Cancer 10(3):198-202, 2011. e-Pub 2011. PMID: 21855043.
119. Weissferdt A, Moran CA. Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis. Am J Surg Pathol 35(9):1305-10, 2011. e-Pub 2011. PMID: 21836478.
120. Weissferdt A, Moran CA. Thymic carcinoma associated with multilocular thymic cyst: A clinicopathologic study of 7 cases. Am J Surg Pathol 35(7):1074-9, 2011. e-Pub 2011. PMID: 21677542.
121. Weissferdt A, Hernandez JC, Kalhor N, Moran CA. Spindle cell thymomas: An immunohistochemical study of 30 cases. Appl Immunohistochem Mol Morphol 19(4):329-35, 2011. e-Pub 2011. PMID: 21386704.
122. Weissferdt A, Kalhor N, Suster S. Malignant mesothelioma with prominent adenomatoid features: A clinicopathologic and immunohistochemical study of 10 cases. Ann Diagn Pathol 15(1):25-9, 2011. e-Pub 2011. PMID: 21106421.
123. Langman G, Andrews CL, Weissferdt A. WT1 expression in salivary gland pleomorphic adenomas: A reliable marker of the neoplastic myoepithelium. Mod Pathol 24(2):168-74, 2011. e-Pub 2011. PMID: 21057459.
124. Weissferdt A, Kalhor N, Suster S, Moran CA. Primary angiosarcomas of the anterior mediastinum: A clinicopathologic and immunohistochemical study of 9 cases. Hum Pathol 41(12):1711-7, 2010. e-Pub 2010. PMID: 20709359.
125. Weissferdt A, Kalhor N, Suster S, Moran CA. Adenomatoid spindle cell thymomas: A clinicopathological and immunohistochemical study of 20 cases. Am J Surg Pathol 34(10):1544-9, 2010. e-Pub 2010. PMID: 20852406.
126. Weissferdt A, Langman G. An intracapsular carcinoma ex pleomorphic adenoma with lung metastases composed exclusively of benign elements: Histological evidence of a continuum between metastasizing pleomorphic adenoma and carcinoma ex pleomorphic adenoma. Pathol Res Pract 206(7):480-3, 2010. e-Pub 2010. PMID: 19665316.
127. Weissferdt A, Maheshwari MB, Downey GP, Rollason TP, Ganesan R. Cotyledonoid dissecting leiomyoma of the uterus: A case report. Diagn Pathol 2:18, 2007. e-Pub 2007. PMID: 17567915.
128. Weissferdt A, Neuling K, English M, Arul S, McMullan D, Ely A, Bründler MA, Brown R. Primitive peripheral neuroectodermal tumour with neuroblastoma like differentiation. Pediatr Dev Pathol 9(3):229-33, 2006. e-Pub 2006. PMID: 16944972.
129. Gebert A, Fassbender S, Werner K, Weissferdt A. The development of M cells in Peyer's patches is restricted to specialized dome-associated crypts. Am J Pathol 154(5):1573-82, 1999. e-Pub 1999. PMID: 10329609.
130. Gebert A, Fassbender S, Weissferdt A, Preiss G. Detection of glycoconjugates by lectin gold labelling, silver enhancement, and scanning electron microscopy. J Electron Microsc (Tokyo) 48(1):85-7, 1999. e-Pub 1999. PMID: 10101873.

Invited Articles

1. den Bakker, MA, Weissferdt, A. Neurogenic tumours of the posterior mediastinum and differential diagnosis considerations. Histopathology 84(1):238-252, 2024. e-Pub 2024. PMID: 37771117.
2. Weissferdt, A. Common thymomas: classification, histology, staging and prognosis. Diagnostic Histopathology 29(2):94-104, 2023. e-Pub 2023.
3. Syred K, Weissferdt A. Primary mediastinal synonvial sarcoma. Mediastinum 4(13), 2020. e-Pub 2020. PMID: 35118281.
4. Weissferdt A. Large cell carcinoma of lung: On the verge of extinction?. Semin Diagn Pathol 31(4):278-88, 2014. e-Pub 2014. PMID: 25023633.

Review Articles

1. Alqaidy, D, Fang, H, Moran, CA, Medeiros, LJ, Weissferdt, A. From the archives of MD Anderson Cancer Center. Annals of Diagnostic Pathology 81, 2026. e-Pub 2026. PMID: 41483625.
2. Berezowska S, Keyter M, Bouchaab H, Weissferdt A. Pathology of Surgically Resected Lung Cancers Following Neoadjuvant Therapy. Adv Anat Pathol 31(5):324-332, 2024. e-Pub 2024. PMID: 38595110.
3. Weissferdt A. Combined thymic epithelial neoplasms – a review. Int J Surg Pathol 31(6):10668969221118324, 2023. e-Pub 2023. PMID: 36036356.
4. Weissferdt A, Moran CA. Atypical thymoma (epithelial-rich thymoma, well-differentiated thymic carcinoma, WHO type B3 thymoma): A conundrum. Pathol Res Pract 245:154459, 2023. e-Pub 2023. PMID: 37043966.
5. Weissferdt A. Spindle cell thymoma and its histological mimickers. Mediastinum 7, 2023. e-Pub 2023. PMID: 37701646.
6. Weissferdt A. The spectrum of sebaceous differentiation in tumors of thymic origin. Pathol Res Pract 229:153702, 2022. e-Pub 2022. PMID: 34929596.
7. Syred K, Morrison I, Weissferdt A. Benign tumours of the bronchopulmonary system. Histopathology 78(7):918-931, 2021. e-Pub 2021. PMID: 33629377.
8. Weissferdt A, Pataer A, Swisher SG, Heymach JV, Gibbons DL, Cascone T, Sepesi B. Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment. Lung Cancer 154:76-83, 2021. e-Pub 2021. PMID: 33631448.
9. Syred K, Weissferdt A. Non-Neoplastic Mediastinal Cysts. Adv Anat Pathol 27(5):294-302, 2020. e-Pub 2020. PMID: 31972565.
10. Hamza A, Weissferdt A. Non-Neoplastic and Benign Tumoral Lesions of the Thymic Gland: A Review and Update. Adv Anat Pathol 26(4):257-269, 2019. e-Pub 2019. PMID: 30932971.
11. Weissferdt A. Pulmonary Sarcomatoid Carcinomas: A Review. Adv Anat Pathol 5(25):304-313, 2018. e-Pub 2018. PMID: 29912718.
12. Kalhor N, Weissferdt A, Moran CA. Primary salivary gland type tumors of the thymus. Adv Anat Pathol 24(1):15-23, 2017. e-Pub 2017. PMID: 27941539.
13. Weissferdt A, Moran CA. The spectrum of ectopic thymomas. Virchows Arch 469(3):245-54, 2016. e-Pub 2016. PMID: 27255665.
14. Piña-Oviedo S, Weissferdt A, Kalhor N, Moran CA. Primary Pulmonary Lymphomas. Adv Anat Pathol 22(6):355-75, 2015. e-Pub 2015. PMID: 26452211.
15. Weissferdt A, Moran CA. Reclassification of early stage pulmonary adenocarcinoma and its consequences. J Thorac Dis 6(S5):S581-8, 2014. e-Pub 2014. PMID: 25349709.
16. Weissferdt A, Moran CA. Immunohistochemistry in the Diagnosis of Thymic Epithelial Neoplasms. Appl Immunohistochem Mol Morphol 22(7):179-87, 2014. e-Pub 2014. PMID: 24897066.
17. Weissferdt A, Moran CA. Epithelioid hemangioendothelioma of the bone: a review and update. Adv Anat Pathol 21(4):254-9, 2014. e-Pub 2014. PMID: 24911250.
18. Weissferdt A, Walsh G, Kaiser L, Moran CA. Pulmonary adenocarcinoma T1N0M0 and its classification. Semin Diagn Pathol 31(4):260-4, 2014. e-Pub 2014. PMID: 25012478.
19. Weissferdt A, Moran CA. The histomorphologic spectrum of spindle cell thymoma. Hum Pathol 45(3):437-45, 2014. e-Pub 2014. PMID: 23260329.
20. Weissferdt A, Moran CA. Staging of thymic epithelial neoplasms: thymoma and thymic carcinoma. Pathol Res Pract 211(1):2-11, 2014. e-Pub 2014. PMID: 25441660.
21. Weissferdt A, Kalhor N, Moran CA. Well-differentiated adenocarcinoma-bronchioloalveolar carcinoma-in situ adenocarcinoma: a conundrum. Adv Anat Pathol 20(5):347-51, 2013. e-Pub 2013. PMID: 23939151.
22. Weissferdt A, Moran CA. Staging of primary mediastinal tumors. Adv Anat Pathol 20(1):1-9, 2013. e-Pub 2013. PMID: 23232566.
23. Weissferdt A, Wistuba II, Moran CA. Molecular aspects of thymic carcinoma. Lung Cancer 78(2):127-32, 2012. e-Pub 2012. PMID: 22921473.
24. Weissferdt A, Suster S, Moran CA. Primary mediastinal "thymic" seminomas. Adv Anat Pathol 19(2):75-80, 2012. e-Pub 2012. PMID: 22313835.
25. Weissferdt A, Moran CA. Malignant biphasic tumors of the lungs. Adv Anat Pathol 18(3):179-89, 2011. e-Pub 2011. PMID: 21490435.
26. Weissferdt A, Moran CA. Primary vascular tumors of the lungs: a review. Ann Diagn Pathol 14(4):296-308, 2010. e-Pub 2010. PMID: 20637438.

Other Articles

1. Weissferdt A The Author's Reply:144:677, 2015.

Editorials

1. Weissferdt, A. Pulmonary neuroendocrine carcinomas - evidence for a spectrum of differentiation. Virchows Arch 4(472):579-580, 2018. PMID: 29388011.
2. Weissferdt A, Kalhor N, Moran CA. Lung carcinoma: Beyond the WHO classification. Semin Diagn Pathol 31(4):259, 2014. PMID: 25002355.

Abstracts

1. Weissferdt A. Pulmonary Amphicrine Carcinomas: Report of 5 Additional Cases of Carcinomas with Mucinous and Neuroendocrine Differentiation. 15th Joint Meeting of the British Division of the International Academy of Pathology (BDIAP) and the Pathological Society of Great Britain and Ireland, joint with the Belgian Society of Pathology, 2025. e-Pub 2025.
2. Han J, Ding Y, Hameed N, Weissferdt A, Sun H. TRPS1 and GATA3 Expression in SMARCA4 Deficient Malignant Neoplasms 105(3):102968, 2025. e-Pub 2025.
3. Tomczak K, Ozirmak Lermi N, Deboever N, Li S, Isgandarova S, Stanford MD, Ramos C, Oliva J, Medina Rosales MN, Koksoy AA, Wu CJ, Strange CD, Weissferdt A, Chen K, Rice DC, Mehran RJ, Zhang J, Sepesi B, Altan M, Tsao A, Haymaker CL. An integrated tumor, immune and genetic landscape of pleural mesothelioma to unleash effective immunotherapy avenues. Society for Immunotherapy of Cancer Annual Meeting, 2024. e-Pub 2024.
4. Ozirmak N, Molina M, Hernandez S, Serrano A, Tomczak KJ, Lu W, Khan K, Barnes S, Dou J, Liang Q, Jiang M, Sanchez-Espiridion B, Weissferdt A, Heymach J, Zhang J, Sepesi B, Cascone T, Tsao A, Altan M, Mehran RJ, Gibbons D, Wistuba II, Haymaker CL, Chen K, Solis Soto LM. Comparison of Spatial transcriptomic platforms in FFPE TMA samples. Society for Immunotherapy of Cancer Annual Meeting, 2024. e-Pub 2024.
5. Koksoy A, Oliva-Ramirez JL, Tomczak K, Stanford MD, Deboever N, Pandurengan R, Medina Rosales M, Lermi NO, Strange CD, Parra Cuentas E, Weissferdt A, Chen K, Rice DC, Zhang J, Solis Soto L, Sepesi B, Mehran RJ, Altan M, Tsao A, Haymaker CL. Analysis of PD1+ T Cells and LS Presence in Pleural Mesothelioma Using Spatial and Machine Learning Approaches. Society for Immunotherapy of Cancer Annual Meeting, 2024. e-Pub 2024.
6. Oliva-Ramirez JL, Tomczak K, Stanford MD, Lu H, Deboever N, Li S, Medina Rosales M, Koksoy AA, Ozirmak Lermi N, Strange CD, Weissferdt A, Chen K, Rice DC, Zhang J, Sepesi B, Mehran RJ, Altan M, Tsao A, Haymaker CL. Functional and transcriptomic evaluation of pleural mesothelioma tumor expanded infiltrating lymphocytes and their TCR repertoire. Society for Immunotherapy of Cancer Annual Meeting, 2024. e-Pub 2024.
7. Haymaker CL, Tomczak K, Ozirmak Lermi N, Oliva-Ramirez L, Deboever N, Ramos C, Kumar G, Rosales M, Lu H, Stanford MD, Strange CD, Weissferdt A, Chen K, Dc R, Mehran RJ, Zhang J, Altan M, Tsao A. Decoding the tumor immune microenvironment to unleash effective immunotherapy avenues for epithelioid malignant pleural mesothelioma. ESMO Lung Cancer Congress, 2024. e-Pub 2024.
8. Sepesi B, Feldman H, Jr WW, Lin H, Leung CH, Weissferdt A, Pataer A, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Negrao MV, Tsao AS, Gibbons DL, Lee JL, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical Outcomes After Chemotherapy plus Nivolumab and Chemotherapy plus Nivolumab and Ipilimumab in Patients with Non-Small Cell Lung Cancer. American Association for Thoracic Surgery Annual Meeting, 2023. e-Pub 2023.
9. Deutsch JS, Cottrell TR, Chen K, de Andrea CE, Fiset PO, Orr C, Rodriguez-Canales J, Salgado R, Schurch C, Scolyer RA, Seethala R, Sholl LM, Signoretti S, Michael Tetzlaff M, Weissferdt A, Xu X, Ziai J, Wang H, Baras AS, Cimino-Mathews A, Taube JM. Pan-tumor harmonization of pathologic response assessment for standardized data collection in neoadjuvant IO trials (PATHdata): Interim analysis of a multi-institutional reproducibility study. 38th Annual Meeting of the Society of Immunotherapy of Cancer, 2023. e-Pub 2023.
10. Weissferdt A, Leung H, Sepesi B, William WN, Lin H, Mehran RJ, Gibbons DL, Vaporciyan A, Heymach JV, Swisher SG, Lee JJ, Cascone T, Pataer A. Pathologic patterns following different neoadjuvant therapies in non-small cell lung cancer (NSCLC). ESMO Congress, 2023. e-Pub 2023.
11. Wang K, Rojas Alvarez F, Leung CH, Kemp H, Lewis WE, Arrachedera CA, Solis Soto L, Blumenschein G, Sepesi B, Skoulidis F, Heymach JV, Gibbons DL, Zhang J, Wistuba II, Lee JJ, Weissferdt A, Swisher SG, Pataer A, Cascone T, Negrao MV. Neoadjuvant chemotherapy or chemo-immunotherapy in resectable KRAS-mutated non-small cell lung cancer (NSCLC) patients: single center experience. World Lung Cancer Conference, 2023. e-Pub 2023.
12. Tomczak K, Ozirmak Lermi N, Deboever N, Zhou N, Jiang X, Ramos C, Oliva-Ramirez JL, Kumar G, Stanford M, Wu CJ, Strange CD, Weissferdt A, Chen K, Rice DC, Mehran RJ, Zhang J, Altan M, Tsao A, Sepesi B, Haymaker CL. Diversity of tumor immune microenvironment landscape of epithelioid malignant pleural mesothelioma in patients with primary surgically resected tumors. 16th International Conference of the International Mesothelioma Interest Group, 2023. e-Pub 2023.
13. Tomczak K, Oliva-Ramirez JL, Ramos C, Stanford M, Deboever N, Zhou N, Kumar G, Ozirmak Lermi N, Strange CD, Weissferdt A, Chen K, Rice DC, Mehran RJ, Zhang J, Altan M, Tsao A, Sepesi B, Haymaker CL. Deciphering dysfunctional heterogeneity of tumor-infiltrating lymphocytes from malignant pleural mesothelioma. 16th International Conference of the International Mesothelioma Interest Group, 2023. e-Pub 2023.
14. Nelson DB, Pataer A, Correa AM, Weissferdt A, Antonoff MB, Cascone T, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Walsh GL, Roth JA, Vaporciyan AA, Heymach JV, Sepesi B, Swisher SG. Relevance of pathologic downstaging after neoadjuvant chemotherapy for lung cancer. General Thoracic Surgical Club Annual Meeting, 2023. e-Pub 2023.
15. Deboever N, McGrail DJ, Zhou N, Altan M, Olivia JL, Parra E, Zhang J, Lee PP, Rajaram R, Hofstetter WL, Vaporciyan AA, Mehran RJ, Rice DC, Tomczak K, Weissferdt A, Tsao AS, Haymaker CL, Sepesi B. Clinical and environment factors impacting malignant pleural mesothelioma prognosis 33(2):S89-S90, 2022. e-Pub 2022.
16. Tomczak K, Ramos C, Deboever N, Zhou N, Oliva JL, Wu CJ, Strange CD, Weissferdt A, Rice DC, Mehran RJ, Zhang J, Altan M, Tsao A, Sepesi B, Haymaker CL. Single cell transcriptome and epigenome profiling reveals the diversity of T cell states in ex vivo grown tumor-infiltrating lymphocytes from malignant pleural mesothelioma. SITC 37th Annual Meeting, 2022. e-Pub 2022.
17. Bota-Rabassedas N, Wijeratne S, Connolly C, Wynes MW, Sanchez-Espiridion B, Fujimoto J, Posadas J, Walker A, Zhu H, Dacic S, Travis WD, Lee JJ, Kerr K, Glass C, Saqi A, Sholl L, Cooper W, Roden A, Poleri C, Chung J, Lopez Martin J, Borczuk A, Weissferdt A, Wistuba II. Infrastructure for interobserver variability assessment of pathologic response in surgical resection specimens following neoadjuvant immune check point inhibitor therapies in early stage NSCLC. IASLC 2022 North America Conference on Lung Cancer, 2022. e-Pub 2022.
18. Li Z, Hubert SM, Zhang R, Song X, Karpinets T, Weissferdt A, Little L, Mohammad M, Gumbs C, Negrao MV, Zhang J, Pataer A, Swisher S, Vaporciyan AA, Roth JA, Heymach JV, Sepesi B, Gibbons DL, Fang B, Zhang J. Molecular parameters impacting the success rate of a lung cancer PDX model 40(16):e20592, 2022. e-Pub 2022.
19. Zhou N, Sepesi B, Leung CH, Lin HY, William WN, Weissferdt A, Pataer A, Godoy M, Fossella FV, Blumenschein G, Le X, Tsao AS, Zhang J, Hofstetter WL, Swisher S, Vaporciyan AA, Lee JJ, Gibbons DL, Heymach JV, Cascone T. Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study 39(15):8542, 2021. e-Pub 2021.
20. Nelson DB, Mitchell KG, Wang J, Fujimoto J, Behrens C, Zheng X, Zhang J, Sepesi B, Vaporciyan AA, Hofstetter WL, Mehran RJ, Rice DC, Walsh GL, Swisher SG, Moran CA, Kalhor N, Weissferdt A, Wistuba II, Roth JA, Antonoff MA. Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities:103A, 2019. e-Pub 2019.
21. Cascone T, Jr WW, Weissferdt A, Lin H, Leung CH, Carter B, Fossella FV, Mott FE, Papadimitrakopoulou VA, Jr BG, Le X, Federico L, Parra ER, Bernatchez C, Wistuba II, Vaporciyan AA, Gibbons DL, Swisher SG, Heymach JV, Sepesi B. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): clinical and translational results from the NEOSTAR study 37:8504A, 2019. e-Pub 2019.
22. Sepesi B, Cascone T, Jr WW, Lin H, Leung CH, Weissferdt A, Walsh G, Rice DC, Roth JA, Mehran RJ, Hofstetter W, Antonoff M, Heymach JV, Gibbons D, Papadimitrakopolou V, Fossella F, Mott F, Le X, Blumenschein G, Vaporciyan AA, Swisher SG. Surgical outcomes following neoadjuvant nivolumab or nivolumab plus ipilimumab in non-small cell lung cancer - NEOSTAR study 14:S241-S242, 2019. e-Pub 2019.
23. Xu XM, Kalhor N, Fujimoto J, Weissferdt A, Solis L, Wistuba I, Moran CA. p16 FISH and BAP1 immunohistochemistry in sarcomatoid mesotheliomas 32(2):1889A, 2019. e-Pub 2019.
24. Hamza A, Liu S, Rubin M, Weissferdt A, Mehran RJ, Wistuba II, Moran CA, Kalhor N. Lymph node metastasis does not confer a poor prognosis in typical carcinoid tumor of the lung 32(2):1835A, 2019. e-Pub 2019.
25. Mitchell KG, Negrao MV, Parra ER, Li J, Reuben A, Vaporciyan AA, Swisher SG, Roth JA, Lacerda L, Wistuba II, Bernatchez C, Haymaker CL, Futreal A, Chow CB, Zhang J, Tran HT, Vasquez ME, Prado E, Rodriguez-Canales J, Celestino M, Weissferdt A, Roarty E, Cascone T, Gibbons DL, Heymach JV, Zhang J, Sepesi B. Clinicopathological and immune microenvironment features associated with high tumor mutational burden and PD-L1 expression in resected non–small-cell lung cancer:293A, 2019. e-Pub 2019.
26. Mitchell KG, Parra ER, Nelson DB, Corsini E, Zhang J, Vaporciyan AA, Hofstetter WL, Mehran RJ, Swisher SG, Rice DC, Sepesi B, Walsh GL, Behrens C, Kalhor N, Weissferdt A, Moran CA, Skoulidis F, Wistuba II, Fujimoto J, Roth JA, Antonoff MB. Intratumoral LKB1/STK11 expression correlates with immune cell infiltration and oncologic outcomes following resection of lung adenocarcinoma:292A, 2019. e-Pub 2019.
27. Weissferdt A, Cascone T, Pataer A, Kalhor N, Moran CA, Antonoff MB, Walsh G, Bernatchez C, Gibbons D, Wistuba I, Roth J, Zhang J, Roarty E, Landry LC, Vaporciyan AA, Heymach JV, Swisher SG, Sepesi B. Histopathologic parameters define features of treatment response to neoadjuvant chemotherapy in non-small cell lung cancer 13(10S):P3 09-27, 2018. e-Pub 2018.
28. Weissferdt A, Sepesi B, Pataer A, Kalhor N, Moran CA, William WN, Le X, Glisson B, Skoulidis F, Blumenschein G, Zhang J, Altan M, Rice D, Mehran RJ, Lee JJ, Vaporciyan AA, Gibbons DL, Swisher SG, Heymach JV, Cascone T. Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC) 29(8):1928P, 2018. e-Pub 2018.
29. Cascone T, William WN, Weissferdt A, Leung CH, Federico L, Haymaker C, Bernatchez C, Fossella FV, Mott FE, Papadimitrakopoulou VA, Byers L, Lam VK, Godoy MC, Carter B, Lee JJ, Vaporciyan AA, Gibbons DL, Swisher SG, Heymach JV, Sepesi B. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC) 29(8):LBA49, 2018. e-Pub 2018.
30. Francisco Cruz A, Parra E, Jiang M, Fujimoto J, Krishnan S, Barua S, Rao A, Chow C, Behrens C, Kalhor N, Weissferdt A, Heymach J, Swisher S, Sepesi B, Lee J, Moran CA, Futreal PA, Zhang J, Wistuba II. Characterization of the immunologic intra-tumor heterogeneity in early stages of non-small cell lung cancer by multiplex immunofluorescence 13(10S):OA 03-05, 2018. e-Pub 2018.
31. Salazar R, Solorzano J, Solis L, Behrens C, Mino B, Parra E, Zhang J, Vaporciyan AA, Rice D, Kalhor N, Moran CA, Gibbons D, Weissferdt A, Sepesi B, Wistuba II. CD73 immunohistochemical expression in malignant cells and correlation with immune infiltrate in nonsmall cell lung carcinoma (NSCLC) 13(10S):P1.04-22, 2018. e-Pub 2018.
32. Sepesi B, Federico L, Mitchell K, Parra E, Francisco Cruz A, Ravelli A, Haymaker C, Karpinets T, Cascone T, Weissferdt A, Antonoff MB, Walsh G, Bernatchez C, Roth J, Zhang J, Roarty E, Landry L, Vaporciyan AA, Swisher SG, Heymach J, Wistuba II, Gibbons D. PD-L1 expression is predominant in CD68+ tumor-associated macrophages in stage I-III non-small celllung cancers 13(10S):P1.03-12, 2018. e-Pub 2018.
33. Negrao M, Reuben A, Chen R, Sepesi B, Karpinets T, Parra E, Federico L, Vence L, Weissferdt A, Tran H Vaporciyan AA, Haymaker C, Forget M, Vasquez M, Prado E, Chow C, Zhang J, Fujimoto J, Roth JA, Meraz, IM, Roarty E, Landry L, Wagner H, Bogatenkova E, Bernatchez C, Futreal PA, Wistuba II, Swisher SG, Heymach J, Gibbons D, Zhang J. Prospective immunogenomic profiling of non-small cell lung cancer: genomic and immune profiling updates from project ICON 13(10S):MA.06.02, 2018. e-Pub 2018.
34. Parra ER, Villalobos P, Zhang J, Behrens C, Mino B, Moran CA, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Heymach J, Lee JJ, Zhang J, Gibbons D, Rodriguez-Canales J, Wistuba II. Image analysis-based expression of nine immune checkpoints identifies distinct immunoprofiling patterns in non-small cell lung carcinomas 12:S823-S824, 2017. e-Pub 2017.
35. Weissferdt A, Kalhor N, Moran CA. Metastatic basal cell carcinomas to thorax and bone: a clinicopathological and immunohistochemical study of 14 cases 30(2):498A, 2017. e-Pub 2017.
36. Behrens C, Parra ER, Rodriguez-Canales J, Villalobos P, Sepesi B, Weissferdt A, Kalhor N, Heymach J, Moran CA, Gibbons D, Wistuba II. Sex differences are detected in the profile of tumor associated inflammatory cells (TAICS) in lung adenocarcinoma 12:S323-S324, 2017. e-Pub 2017.
37. Sepesi B, Cuentes EP, Canales JR, Behrens C, Correa A, Antonoff M, Gibbons DL, Heymach J, Hofstetter W, Mehran R, Rice DC, Roth J, Vaporciyan AA, Walsh G, Weissferdt A, Kalhor N, Moran C, Swisher SG, Wistuba I. Tumor-infiltrating lymphocytes and overall survival in surgically resected stage II and III non-small cell lung cancer 98:223, 2017. e-Pub 2017.
38. Sepesi, B, Weissferdt A, Vaporciyan A, Futreal A, Karpinets T, Yee C, Haymaker C, Federico L, Forget MA, Lizee G, Talukder A, Roszik J, Tran H, Vasquez M, Prado E, Behrens C, Parra E, Rodriguez-Canales J, Fujimoto J, Vence L, Roth J, Meraz I, Roarty E, Landry L, Byers L, Swisher SG, William Jr W, Sharma, Allison J, Bingliang, Zhang J, Wagner H, Bogatenkova E, Wistuba II, Heymach JV, Chantale, Gibbons DL. Prospective ImmunogenomiC PrOfiling of Non-small cell lung cancer (ICON Project) 12:S324-S325, 2017. e-Pub 2017.
39. Parra ER, Behrens C, Rodriguez-Canales J, Jiang M, Pataer A, Correa AM, Swisher S, Sepesi B, Weissferdt A, Kalhor N, William WN, Lee JJ, Heymach J, Moran CA, Zhang J, Gibbons D, Wistuba II. The influence of neoadjuvant chemotherapy, on immune response profile in non-small cell lung carcinomas 12:S323-S324, 2017. e-Pub 2017.
40. Weissferdt A, Ramineni M, Kalhor N, Moran CA. Pleomorphic carcinomas of the lung: a clinicopathological and immunohistochemical study of 68 cases 29(S2):487A, 2016. e-Pub 2016.
41. Ramineni M, Weissferdt A, Swisher SG, Moran CA, Kalhor N. Combined high-grade neuroendocrine lung carcinomas: a clinicopathologic study of surgical resection cases from a single institution 29(S2):479A, 2016. e-Pub 2016.
42. Weissferdt A, Ramineni M, Kalhor N, Moran CA. Pure atypical thymomas: a clinicopathological analysis of 25 cases 29(S2):486A, 2016. e-Pub 2016.
43. Weissferdt A, Kalhor N, Fujimoto J, Rodriguez Canales J, Mino B, Nunomura S, Parra Cuentas E, Wistuba II, Moran CA. Expression of PD1 and its ligand PD-L1 in thymic epithelial neoplasms: An immunohistochemical study of 100 cases 28(2):492A, 2015. e-Pub 2015.
44. Weissferdt A, Kalhor N, Liu H, Rodriguez Canales J, Fujimoto J, Wistuba II, Moran CA. Pulmonary spindle cell carcinomas: A clinicopathological and immunohistochemical study of 40 cases 28(2):492A, 2015. e-Pub 2015.
45. Weissferdt A, Kalhor N, Liu H, Rodriguez J, Fujimoto J, Tang X, Wistuba II, Moran CA. Paraganglioma versus thymic carcinoid tumor: an immunohistochemical study of 46 cases 27(2):499A, 2014. e-Pub 2014.
46. Liu H, Mino B, Parra E, Fujimoto J, Tang X, Weissferdt A, Kalhor N, Wistuba II, Moran CA, Rodriguez J. Effects of long term slide storage on PTEN antigenicity: implications for clinical trials and translational research 27(2):525A, 2014. e-Pub 2014.
47. Mino B, Roy-Chowdhuri S, Gonzalez I, Kiriakova G, Liu H, Fujimoto J, Tang X, Weissferdt A, Kalhor N, Wistuba II, Moran CA, Rodriguez-Canales J. Optimization of a cell transfer technique for multiple immunocytochemistry from single cytology smears for pathology and translational research 27(2):526A, 2014. e-Pub 2014.
48. Fujimoto J, Zhang J, Pickering CR, Kadara H, Liu CG, Drummond JA, Muzny DM, Doddapaneni HV, Weissferdt A, Wheeler DA, Myers JN, Wang J, Wistuba II, Kalhor N, Moran CA. Identification of novel somatic variants in thymic epithelial tumors by next-generation sequencing 27(2):477A, 2014. e-Pub 2014.
49. Weissferdt A, Moran CA. Mediastinal seminomas with florid follicular hyperplasia: a clinicopathological and immunohistochemical study of 6 cases 27(2):498A, 2014. e-Pub 2014.
50. Weissferdt A, Kalhor N, Liu H, Rodriguez J, Fujimoto J, Tang X, Wistuba II, Moran CA. Primary mediastinal seminomas: a comprehensive immunohistochemical study using novel markers 27(2):498A, 2014. e-Pub 2014.
51. Weissferdt A, Phan AT, Suster S, Moran CA. Adenocortical Carcinomas: A clinicopathological analysis of 77 cases 26(1):139A, 2013. e-Pub 2013.
52. Weissferdt A, Kalhor N, Moran CA. Comparative immunohistochemical analysis of pulmonary and thymic neuroendocrine carcinomas using Pax8 and TTF-1 26(1):469A, 2013. e-Pub 2013.
53. Weissferdt A, Phan AT, Suster S, Moran CA. Adrenocortical Carcinomas: An immunohistochemical analysis of 40 cases 26(1):139A, 2013. e-Pub 2013.
54. Farjo B, Murugan A, Weissferdt A. A case of severe hypoxic respiratory failure caused by an unusual presentation of primary bronchogenic adenocarcinoma 142:602A, 2012. e-Pub 2012.
55. Tchakarov A, Weissferdt A, Buja M. Hepatic compartment syndrome leading to fulminant hepatic failure: 136:1052, 2012. e-Pub 2012.
56. Weissferdt A, Hernandez JC, Kalhor N, Moran CA. Spindle cell thymomas: An immunohistochemical study of 30 cases 57(1):667, 2010. e-Pub 2010.
57. Weissferdt A, Kalhor N, Suster S, Moran CA. Microcystic spindle cell thymoma: A clinicopathological study of 20 cases 134:1343, 2010. e-Pub 2010.
58. Langman G, Andrews CL, Weissferdt A. WT-1 expression in salivary gland pleomorphic adenomas: A reliable marker of neoplastic myoepithelium 23(1):275A, 2010. e-Pub 2010.
59. Weissferdt A, Hernandez JC, Kalhor N, Moran CA. Pancytokeratin, cytokeratin 5/6, cytokeratin 7, cytokeratin 20, TTF-1 and p63 as a diagnostic tool separating non-small cell lung carcinomas in biopsy specimens 57(1):611, 2010. e-Pub 2010.
60. Weissferdt A, Kalhor N, Suster S, Moran CA. Pleural malignant mesothelioma with prominent adenomatoid features: A clinicopathological and immunohistochemical study of 10 cases 57(1):607, 2010. e-Pub 2010.
61. Weissferdt A, Saldana G, Fletcher A. Problems in histological reporting caused by small malorientated skin specimens 201:58A, 2003. e-Pub 2003.

Book Chapters

1. Chan JKC, Thompson LD, Weissferdt A. Biphenotypic branchioma. In: WHO Classification of Tumours of the Head and Neck. 5th. IARC, 2024.
2. Nonaka D, Tateyama H, Weissferdt A. Adenosquamous carcinoma of the thymus. In: WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 5th. IARC, 2021.
3. Weissferdt A, Chalabreysse L, Weis CA. Ectopic thyroid tumours. In: WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 5th. IARC, 2021.
4. Weissferdt A, Chalabreysse L, Weis CA. Ectopic parathyroid tumours. In: WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 5th. IARC, 2021.
5. Nonaka D, Tateyama H, Weissferdt A. Thymic carcinoma, NOS. In: WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 5th. IARC, 2021.
6. Weissferdt A, Moran CA. Pathology and staging of thymic neoplasms. In: Modern Thoracic Oncology. 1st. World Scientific Publishing, 2018.
7. Weissferdt A, Moran CA. Immunohistology of the mediastinum. In: Diagnostic immunohistochemistry: Theranostic and genomic applications. 5th. Elsevier Saunders, 2018.
8. Weissferdt A, Kalhor N, Moran CA. Immunohistology of the lung and pleura. In: Diagnostic immunohistochemistry: Theranostic and genomic applications. 5th. Elsevier Saunders, 2018.
9. Weissferdt A, Moran CA. Mediastinal sarcomas. In: Enzyclopedia of Pathology - Pathology of the Pleura and Mediastinum. 1st. Springer, 2016.
10. Weissferdt A, Moran CA. Immunohistology of the mediastinum. In: Diagnostic immunohistochemistry: Theranostic and genomic applications. 4th. Elsevier Saunders, 2014.

Books (edited and written)

1. Weissferdt A. Diagnostic Thoracic Pathology. Ed(s) 1st. Springer, 2020.
2. Moran CA, Kalhor N, Weissferdt A. Oncological Surgical Pathology. Ed(s) 1st. Springer, 2020.
3. Weissferdt A, Moran CA. Diagnostic Pathology of Pleuropulmonary Neoplasia. Ed(s) 1st. Springer, 2012.